WELCOME TO OUR PARKINSON'S PLACE!

I HAVE PARKINSON'S DISEASES AND THOUGHT IT WOULD BE NICE TO HAVE A PLACE WHERE THE CONTENTS OF UPDATED NEWS IS FOUND IN ONE PLACE. THAT IS WHY I BEGAN THIS BLOG.

I COPY NEWS ARTICLES PERTAINING TO RESEARCH, NEWS AND INFORMATION FOR PARKINSON'S DISEASE, DEMENTIA, THE BRAIN, DEPRESSION AND PARKINSON'S WITH DYSTONIA. I ALSO POST ABOUT FUNDRAISING FOR PARKINSON'S DISEASE AND EVENTS. I TRY TO BE UP-TO-DATE AS POSSIBLE.

I AM NOT RESPONSIBLE FOR IT'S CONTENTS. I AM JUST A COPIER OF INFORMATION SEARCHED ON THE COMPUTER. PLEASE UNDERSTAND THE COPIES ARE JUST THAT, COPIES AND AT TIMES, I AM UNABLE TO ENLARGE THE WORDING OR KEEP IT UNIFORMED AS I WISH. IT IS IMPORTANT TO UNDERSTAND I AM A PERSON WITH PARKINSON'S DISEASE. I HAVE NO MEDICAL EDUCATION,

I JUST WANT TO SHARE WITH YOU WHAT I READ ON THE INTERNET. IT IS UP TO YOU TO DECIDE WHETHER TO READ IT AND TALK IT OVER WITH YOUR DOCTOR. I AM JUST THE COPIER OF DOCUMENTS FROM THE COMPUTER. I DO NOT HAVE PROOF OF FACT OR FICTION OF THE ARTICLE. I ALSO TRY TO PLACE A LINK AT THE BOTTOM OF EACH ARTICLE TO SHOW WHERE I RECEIVED THE INFORMATION SO THAT YOU MAY WANT TO VISIT THEIR SITE.

THIS IS FOR YOU TO READ AND TO ALWAYS KEEP AN OPEN MIND.

PLEASE DISCUSS THIS WITH YOUR DOCTOR, SHOULD YOU HAVE ANY QUESTIONS, OR CONCERNS. NEVER DO ANYTHING WITHOUT TALKING TO YOUR DOCTOR FIRST..

I DO NOT MAKE ANY MONEY FROM THIS WEBSITE. I VOLUNTEER MY TIME TO HELP ALL OF US TO BE INFORMED.

I WILL NOT ACCEPT ANY ADVERTISEMENT OR HEALING POWERS, HEALING FROM HERBS AND ETC. UNLESS IT HAS GONE THROUGH TRIALS AND APPROVED BY FDA. IT WILL GO INTO SPAM.

THIS IS A FREE SITE FOR ALL WITH NO ADVERTISEMENTS

THANK YOU FOR VISITING! TOGETHER WE CAN MAKE A DIFFERENCE!

TRANSLATE

Tuesday, October 17, 2017

Mousensor, LLC receives NSF SBIA to decode the human sense of smell

October 21, 2017  THE CITY UNIVERSITY OF NEW YORK



MOUSENSOR, LLC has been awarded a National Science Foundation (NSF) Small Business Innovation Research (SBIR) grant for $225,000 to conduct research and development (R&D) work on decoding the human sense of smell.
MouSensor, LLC is an early-stage biotech company that engineers super sniffer mice to build a human-nose-on-a-chip based on fundamental research performed at the Feinstein lab for Neurogenetics at Hunter College, The City University of New York (CUNY). The company's bold vision is to detect, discover and digitize every single smell on this planet -ranging from the fragrances in a perfumer's palette to the Chardonnay in your wine cellar. The company's first target market is the $1.5B Fragrance & Flavor R&D pipeline by providing an objective assay to engineer scents in a rational and streamlined way. By providing a prediction model of how a molecule will smell, Mousensor, LLC enables Fragrance Houses to increase their competitive advantage through the development of unique and sustainable products.
With support of the Michael J Fox Foundation, the company is also employing the MouSensor technology to develop a Parkinson's specific-nose-on-a-chip. Finding a biomarker for (early-stage) Parkinson's disease (PD) is the biggest need in the field right now; a PD nose-on-a-chip has potential applications in patient stratification, treatment monitoring and ultimately as a companion diagnostic.
CUNY has an extensive protection of the background intellectual property, which forms the basis for the MouSensor platform technology. "I have been working with the company from the beginning and is excited that they are in the process of acquiring an exclusive license from CUNY that will further aid in leveraging the technology to the fullest," says Neeti Mitra, Senior Manager, CUNY Technology Commercialization Office
"The National Science Foundation supports small businesses with the most innovative, cutting-edge ideas that have the potential to become great commercial successes and make huge societal impacts," said Barry Johnson, Director of the NSF's Division of Industrial Innovation and Partnerships. "We hope that this seed funding will spark solutions to some of the most important challenges of our time across all areas of science and technology."
"Basically we aim to leverage the human sense of smell which has been fine-tuned through millions of years of evolution and integrate it with state-of-the art silicon chip technology to fully digitize the sense of smell, much like the RGB code for vision," says Dr. Charlotte D'Hulst, co-developer of the platform and CEO of the company.
###
Once a small business is awarded a Phase I SBIR/STTR grant (up to $225,000), it becomes eligible to apply for a Phase II grant (up to $750,000). Small businesses with Phase II grants are eligible to receive up to $500,000 in additional matching funds with qualifying third-party investment or sales.
NSF accepts Phase I proposals from small businesses twice annually in June and December. Small businesses with innovative science and technology solutions, and commercial potential are encouraged to apply. All proposals submitted to the NSF SBIR/STTR program undergo a rigorous merit-based review process.
To learn more about the NSF SBIR/STTR program, visit: http://www.nsf.gov/SBIR.
The National Science Foundation (NSF) awards nearly $190 million annually to startups and small businesses through the Small Business Innovation Research (SBIR)/Small Business Technology Transfer (STTR) program, transforming scientific discovery into products and services with commercial and societal impact. The non-dilutive grants support research and development (R&D) across almost all areas of science and technology helping companies de-risk technology for commercial success. The NSF is an independent federal agency with a budget of about $7 billion that supports fundamental research and education across all fields of science and engineering.
The City University of New York is the nation's leading urban public university. Founded in New York City in 1847, the University comprises 24 institutions: 11 senior colleges, seven community colleges, and additional professional schools. The University serves nearly 275,000 degree-credit students and 218,083 adults, continuing and professional education students. 
For more information, please contact Shante Booker at shante.booker@cuny.edu or visit http://www.cuny.edu/research
Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system

https://www.eurekalert.org/pub_releases/2017-10/tcuo-mln101617.php

No comments:

Post a Comment